Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor

被引：0
|
作者：
Dorien Groenendaal-van de Meent
Martin den Adel
Jan Noukens
Sanne Rijnders
Axel Krebs-Brown
Lyudmila Mateva
Assen Alexiev
Marloes Schaddelee
机构：
[1] Astellas Pharma Europe B.V.,Gastroenterology Clinic
[2] Kinesis Pharma B.V.,Business Development, Transaction Execution Group
[3] University Hospital St Ivan Rilski,undefined
[4] Medical University–Sofia,undefined
[5] COMAC Medical Ltd,undefined
[6] Astellas Pharma Inc.,undefined
来源：
Clinical Drug Investigation | 2016年 / 36卷
关键词：
Chronic Kidney Disease; Hepatic Impairment; Moderate Hepatic Impairment; Normal Hepatic Function; Impaired Hepatic Function;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：743 / 751
页数：8
相关论文
共 50 条
  • [21] Multiwavelength UV-metric and pH-metric determination of the dissociation constants of the hypoxia-inducible factor prolyl hydroxylase inhibitor Roxadustat
    Meloun, Milan
    Pilarova, Lucie
    Javurek, Milan
    Pekarek, Tomas
    JOURNAL OF MOLECULAR LIQUIDS, 2018, 268 : 386 - 402
  • [22] Discovery of DS44470011: An oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of renal anemia
    Fukuda, Takeshi
    Kuribayashi, Takeshi
    Takano, Rieko
    Sasaki, Koji
    Tsuji, Takashi
    Niitsu, Yoichi
    Ishii, Ken
    Hashimoto, Masami
    Baba, Daichi
    Ito, Shuichiro
    Tanaka, Naoki
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2024, 108
  • [23] Discovery of DS-1093a: An oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of renal anemia
    Tanaka, Naoki
    Fukuda, Takeshi
    Takano, Rieko
    Sasaki, Koji
    Tsuji, Takashi
    Goto, Riki
    Kuribayashi, Takeshi
    Yamaguchi, Kyoji
    Niitsu, Yoichi
    Ishii, Ken
    Hashimoto, Masami
    Takahashi, Shinichi
    Obayashi, Hisakuni
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2024, 111
  • [24] Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease
    Kurata, Yu
    Tanaka, Tetsuhiro
    Nangaku, Masaomi
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2020, 29 (04): : 414 - 422
  • [25] Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors and Iron Metabolism
    Ogawa, Chie
    Tsuchiya, Ken
    Maeda, Kunimi
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (03)
  • [26] Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors for Anemia in CKD
    Parfrey, Patrick
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (25): : 2390 - 2391
  • [27] Mucosal protection by hypoxia-inducible factor prolyl hydroxylase inhibition
    Robinson, Andreas
    Keely, Simon
    Karhausen, Joern
    Gerich, Mark E.
    Furuta, Glenn T.
    Colgan, Sean P.
    GASTROENTEROLOGY, 2008, 134 (01) : 145 - 155
  • [28] Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against cisplatin-induced acute kidney injury
    Yang, Yunwen
    Yu, Xiaowen
    Zhang, Yue
    Ding, Guixia
    Zhu, Chunhua
    Huang, Songming
    Jia, Zhanjun
    Zhang, Aihua
    CLINICAL SCIENCE, 2018, 132 (07) : 825 - 838
  • [29] Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against renal ischemia/reperfusion injury by inhibiting inflammation
    Miao, A-Feng
    Liang, Jian-Xiang
    Yao, Lei
    Han, Jun-Ling
    Zhou, Li-Juan
    RENAL FAILURE, 2021, 43 (01) : 803 - 810
  • [30] Hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat (FG-4592) alleviates sepsis-induced acute lung injury
    Han, Fu
    Wu, Gaofeng
    Han, Shichao
    Li, Zhenzhen
    Jia, Yanhui
    Bai, Lu
    Li, Xiaoqiang
    Wang, Kejia
    Yang, Fangfang
    Zhang, Jian
    Wang, Xujie
    Guan, Hao
    Su, Linlin
    Han, Juntao
    Hu, Dahai
    RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY, 2020, 281
12345